|Bid||18.88 x 28000|
|Ask||18.93 x 3100|
|Day's Range||18.87 - 18.97|
|52 Week Range||8.39 - 18.99|
|Beta (3Y Monthly)||2.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2017 - Jul 28, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.87|
Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals (ALDR) (Alder) each filed updated tender offer materials with the U.S. Securities and Exchange Commission (SEC) in connection with Lundbeck's pending tender offer (the Offer), for all outstanding shares of Alder, whereby Alder stockholders are being offered an upfront payment for USD 18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional USD 2.00 per share upon approval of eptinezumab by the European Medicines Agency, representing a total potential consideration of USD 20.00 per share. The Offer commenced on 23 September 2019, and on the same day Lundbeck filed an offer to purchase and related letter of transmittal setting forth the terms of the Offer with the SEC and began mailing such materials to Alder stockholders.
Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD1910 as a preventive treatment for migraine. ALD1910 is an investigational monoclonal antibody (mAb) that inhibits pituitary adenylate cyclase-activating polypeptide (PACAP), an important signaling molecule in the pathophysiology of migraine.
DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […]
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Alder BioPharmaceuticals, Inc. (“Alder” or “the Company”) (NASDAQ: ALDR) for potential breaches of fiduciary duty on the part of its directors in connection with the pending sale of the Company to H. Lundbeck A/S. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
NEW YORK, Sept. 27, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
NEW YORK, Sept. 23, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
The investigation concerns whether United Community and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of United Community to First Defiance Financial Corp. Under the terms of the agreement, United Community shareholders will receive 0.3715 shares of First Defiance common stock for each share of United Community common stock. If you are a United Community shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/united-community-financial-corp-ucfc-first-defiance-merger-stock/.
NEW YORK, NY / ACCESSWIRE / September 20, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in ...
WILMINGTON, Del., Sept. 19, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Alder BioPharmaceuticals, Inc. (NASDAQ GM: ALDR) regarding possible breaches.
BALA CYNWYD, PA / ACCESSWIRE / September 17, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Alder BioPharmaceuticals, Inc. ...
NEW YORK , Sept. 17, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Alder Biopharmaceuticals, Inc. ("Alder" ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Yuma Energy (AMEX: YUMA) shares were up 5.1% ...
The investigation concerns whether Pivotal Software and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Pivotal Software to VMware, Inc. If you are a Pivotal Software shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/pivotal-software-inc-merger-stock-vmware.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder ...
Danish pharmaceutical company H. Lundbeck A/S will acquire Alder Biopharmaceuticals for nearly $2 billion in a deal that sent Alder stock rocketing 84% by the stock market's close on Monday.
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Alder BioPharmaceuticals, Inc. (ALDR) on behalf of Alder shareholders concerning the proposed merger with H. Lundbeck A/S. Pursuant to the proposed transaction, announced on September 16, 2019 and valued at up to $1.95 billion, Alder shareholders will receive $18 in cash and a non-tradeable Contingent Value Right for each share of Alder common stock owned. The Contingent Value Right entitles Alder shareholders to an additional $2 in cash for each share of Alder common stock owned pending the approval of eptinezumab by the European Medicines Agency. The investigation focuses on whether Alder and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
WILMINGTON, DE / ACCESSWIRE / September 16, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR )? Did you purchase any of your shares prior to September 16, ...
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alder BioPharmaceuticals, Inc. (ALDR) to H. Lundbeck A/S (“Lundbeck”) is fair to Alder shareholders. On behalf of Alder shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an Alder shareholder and would like to discuss your legal rights and options, please visit Alder BioPharmaceuticals Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or email@example.com or firstname.lastname@example.org.